Tyra Biosciences reports initial Phase 2 SURF302 results with dabogratinib
Tyra Biosciences reported initial Phase 2 SURF302 results for LG IR NMIBC using dabogratinib.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.